Products added to portfolio are targeted at CNS disorders, infection, and inflammation.
moksha8 expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico, currently generating sales of $140 million.
moksha8 will commercialize products in three therapeutic areas—CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril®, Rocephin®, and Bactrim®.
“moksha8 has established a broad footprint in Latin America, with leading products that are cornerstones of medical care,” said Simba Gill, CEO of moksha8. “We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products.”